To embark on this historical journey, let’s commence with Dr. William Frederic Koch, who formulated a remedy named glyoxylide from herbal ingredients. Dr. Koch achieved a significant breakthrough when he successfully treated his first cancer patient in 1917. Subsequently, he extended his compassionate efforts to assist thousands of others, both directly and indirectly through fellow medical practitioners employing his treatment. It is pertinent to understand the prevailing cancer treatment methodology of that era, which may come as a revelation; it consisted of the same methodologies that had been in practice for over a century, predominantly reliant on x-ray and radium radiation. Remarkably, this approach continues to persist as a principal method in contemporary cancer treatment.
Now, consider this: a century has transpired, and the primary treatment modality for cancer remains largely unaltered. What’s more perplexing is that cancer-related mortality continues to rise. One might understandably question the logic behind this prolonged adherence to a therapeutic approach that, at best, has yielded limited success. Should we not expect those in authority to explore alternative avenues at some juncture? It becomes apparent that pharmaceutical companies predominantly allocate research funds to avenues they believe will not compromise their financial interests.
Dr. Koch articulated a distinctive approach, advocating that the objective should not be to annihilate cancer cells but to eliminate the underlying virus that causes their affliction, thus facilitating their return to normalcy.
Over the years, Dr. Koch faced relentless scrutiny and harassment from the FDA and FTC. In response, he sought refuge in Brazil, where he achieved remarkable successes in treating a broad spectrum of ailments, including advanced rheumatoid arthritis, insanity, diabetes, and even leprosy. This evoked growing concern from the FDA, prompting demands for his return to the United States. Upon his return, he endured unjust arrests on multiple occasions. Despite courtroom trials spanning from 1942 to 1946, during which the judge refused to admit testimonies from cured patients, Dr. Koch was acquitted by two separate juries. These protracted legal proceedings incurred a substantial cost to the government, exceeding $10 million at that time, which translates to approximately $100 million in today’s currency.
However, despite failing to conclusively prove that Dr. Koch’s technology cured cancer, his herbal remedy was no longer accessible within the United States. While he was not legally barred from selling his treatment to doctors, the FTC issued a cease and desist order, which effectively prevented medical practitioners from learning about his medicine and employing it to treat cancer patients.
Colonel Charles March, who assumed the leadership of the FTC and aimed to advocate for Dr. Koch, experienced an untimely and suspicious demise. During that period, and even to this day, it was not uncommon for those involved in alternative medical treatments to encounter similar fates.
It is estimated that over 100,000 patients benefited from successful cancer treatments between 1917, when Dr. Koch healed his inaugural cancer patient, and 1951, when the FTC mandated him to cease advertising to medical practitioners. Regrettably, his laboratories could not sustain operations without sales, and with his passing, along with the limited dissemination of his formula, the cure for cancer and various other illnesses was essentially lost.
The significance of Wain Water becomes evident today, as it emerges as an accessible medicine with affordability at its core. Once it gains wider public recognition and acceptance through rigorous testing, it holds the potential to be beyond the reach of the various regulatory bodies, including the FDA, FTC, and AMA, thus challenging the monopoly of pharmaceutical companies. At that juncture, the era of drugs that solely treat symptoms may draw to a close.
